Reports

Ideas That Generate Results

US Cancer Vaccine Market Analysis

US Cancer Vaccine Market Analysis

Format :  Adobe Reader (PDF) Upto 24 hour delivery
Publish Date : Sep, 2012| No. of Pages : 135

Share |
 
Please make your selection :
Electronic Access - Single User License
US$ 1200.00
CD-ROM Mail Delivery
US$ 1400.00
Hard Copy Mail Delivery
US$ 1400.00
Electronic Access - Multi-User License
US$ 2000.00

List of Figures:

Figure 3-1: Cancer Prevalence (Million), 2008-2016
Figure 3-2: Cancer Incidences (‘000), 2008-2016
Figure 3-3: Cancer Mortality (‘000), 2008-2016
Figure 3-4: Incidences by Type of Cancer (%), 2012
Figure 3-5: Top Five States with Highest Cancer Incidences (‘000), 2012
Figure 3-6: Cancer Incidences by Age Group (%)
Figure 4-1: Global - Cancer Vaccine Market (Billion US$), 2010-2012
Figure 4-2: Cancer Vaccine Market (Billion US$), 2010-2012
Figure 4-3: Share of US in Global Cancer Vaccine Market (2012)
Figure 4-4: Cancer Vaccine Market by Product Type (%), 2012
Figure 4-5: Provenge Market (Million US$), 2010-2012
Figure 4-6: Global - Gardasil Market (Million US$), 2010-2012
Figure 4-7: Gardasil Market (Million US$), 2010-2012
Figure 4-8: Share of US in Global Gardasil Sales (2012)
Figure 4-9: Global - Cervarix Market (Million US$), 2010-2012
Figure 4-10: Cervarix Market (Million US$), 2010-2012
Figure 4-11: Share of US in Global Cervarix sales (2012)
Figure 4-12: Global - Hepatitis B Vaccine Market (Billion US$), 2010-2012
Figure 4-13: Hepatitis B Vaccine Market (Million US$), 2010-2012
Figure 4-14: Global - Engerix-B and Twinrix Market (Million US$), 2010-2012
Figure 4-15: Engerix-B and Twinrix Market (Million US$), 2010-2012
Figure 4-16: Global - Recombivax Market (Million US$), 2010-2012
Figure 4-17: Recombivax Market (Million US$), 2010-2012
Figure 4-18: Global - Pediarix Market (Million US$), 2010-2012
Figure 4-19: Pediarix Market (Million US$), 2010-2012
Figure 5-1: Therapeutic Cancer Vaccines in Phase-3 Clinical Trials by Cancer Site (%)

List of Tables:

Table 3-1: Top 10 Cancer Incidences in Males (2012)
Table 3-2: Top 10 Cancer Incidences in Females (2012)
Table 4-1: Adverse Effects of Gardasil
Table 5-1: Cancers with High Linkage to Virus and Bacteria
Table 5-2: Prophylactic Cancer Vaccines in Phase-4 Clinical Trials
Table 5-3: Prophylactic Cancer Vaccines in Phase-3 Clinical Trials
Table 5-4: Prophylactic Cancer Vaccines in Phase-2 Clinical Trials
Table 5-5: Prophylactic Cancer Vaccines in Phase-1 Clinical Trials
Table 5-6: Therapeutic Cancer Vaccines in Phase-3 Clinical Trials
Table 5-7: Prostate Cancer Therapeutic Vaccines in Phase-3 Clinical Trials
Table 5-8: Prostate Cancer Therapeutic Vaccines in Phase-2 Clinical Trials
Table 5-9: Prostate Cancer Therapeutic Vaccines in Phase-1 and 1/2 Clinical Trials
Table 5-10: Breast Cancer Therapeutic Vaccines in Phase-3 Clinical Trials
Table 5-11: Breast Cancer Therapeutic Vaccines in Phase-2 Clinical Trials
Table 5-12: Breast Cancer Therapeutic Vaccines in Phase-1 and 1/2 Clinical Trials
Table 5-13: Lung Cancer Therapeutic Vaccines in Phase-3 Clinical Trials
Table 5-14: Lung Cancer Therapeutic Vaccines in Phase-2 and 2/3 Clinical Trials
Table 5-15: Lung Cancer Therapeutic Vaccines in Phase-1 and 1/2 Clinical Trials
Table 5-16: Colorectal Cancer Therapeutic Vaccines in Phase-2 Clinical Trials
Table 5-17: Colorectal Cancer Therapeutic Vaccines in Phase-1 and 1/2 Clinical Trials
Table 7-1: Merck - Cancer Vaccines in Pipeline
Table 7-2: GlaxoSmithKline - Cancer Vaccines in Pipeline
Table 7-3: Dendreon - Cancer Vaccines in Pipeline
Table 7-4: Bavarian Nordic - Cancer Vaccines in Pipeline
Table 7-5: Celldex Therapeutics - Cancer Vaccines in Pipeline
Table 7-6: KAEL-GemVax - Cancer Vaccines in Pipeline
Table 7-7: Oxford BioMedica - Cancer Vaccines in Pipeline
Table 7-8: Galena Biopharma - Cancer Vaccines in Pipeline

Not able to find data you are looking for? Ask our Research Analyst.

media citation

get in touch

Please fill-in the information below.